7 Things You Need to Know About Ozempic, Wegovy, and the Weight Loss Revolution
- 9 hours ago
- 13 min read
Stephen Roigard is a registered naturopath, clinical nutritionist, and corporate wellness consultant with over 25 years of experience integrating science-based functional medicine and holistic health to support individuals, professionals, and teams in achieving sustainable wellbeing.
GLP-1 medications are everywhere, in the news, on social media, and probably in your group chat. They genuinely work. But there’s a side of the story that rarely gets told, and it changes everything about how you should approach them. Functional Medicine & Integrative Health Practitioner Stephen Roigard breaks it all down, honestly, without the hype.
This article has been written to share the latest science, in everyday language.
So, what exactly is all the fuss about?
Ozempic and Wegovy (semaglutide), Trulicity (dulaglutide), Mounjaro, and Zepbound (tirzepatide). If you haven’t heard these names yet, you’ve probably been living somewhere blissfully off-grid, and honestly, good for you. For the rest of us, these drugs have been absolutely inescapable. They’re on almost every health podcast, in the news, in celebrity interviews, and popping up in every dinner party conversation.
Here's the thing: the excitement is not entirely unjustified. These medications, a family of drugs known as GLP-1 receptor agonists, originally developed for the management of type 2 diabetes, have produced weight-loss results that genuinely surprised the medical world. Clinical trials show average body weight reductions of 15% or more. For people managing type 2 diabetes or significant obesity, that is a real and meaningful pharmacological advance, and this warrants acknowledgment.
I am not here to tell you these drugs are evil and should be locked in a cupboard forever. That would be both unfair and unhelpful. What I, as a Naturopathic Practitioner, Clinical Nutritionist, and Personal Trainer, am here to do is give you the complete picture: the biology of why they work, the risks that somehow keep getting buried in the small print, and, most importantly, why the current 'take the jab and eat less' approach is missing a crucial piece of the puzzle for the vast majority of people.
Think of this as the conversation your prescription didn’t come with.
What is GLP-1 & why should you care?
GLP-1 stands for glucagon-like peptide-1. Don’t let the name put you off, it’s actually doing something rather elegant in your body every time you eat.
GLP-1 is a hormone produced naturally in your gut after a meal. Its job is to coordinate your body’s response to food, a bit like an air traffic controller for your metabolism. It does three main things:
It slows down how quickly food leaves your stomach, which means you feel fuller for longer and your blood sugar doesn’t spike dramatically after eating.
It tells your liver to stop releasing stored sugar into your bloodstream, and this, interestingly, also brings insulin levels down rather than pushing them up. Lower insulin means your body is more likely to burn stored fat rather than stockpile more of it.
It communicates directly with your brain’s appetite centers and essentially says, 'Right, that’s enough, you’re done.' Your hunger switches off, and fullness kicks in.
The GLP-1 drugs work by mimicking this hormone, but at much higher-than-natural levels. The result is a very powerful, sustained version of all three effects, which is why people are eating significantly less without feeling particularly hungry. It’s genuinely clever biology.
One common misconception worth clearing up: GLP-1 does not primarily work by increasing insulin secretion (as most people, and even some clinicians, assume). Research from Professor Arne Astrup’s group at the University of Copenhagen, one of the leading GLP-1 research teams in the world, has shown that GLP-1 actually reduces both insulin and blood glucose after a meal, mainly by suppressing glucagon and slowing the emptying of the stomach. That distinction matters a great deal for understanding what these drugs actually do to your metabolism.
Why 'losing weight' & 'losing fat' are not the same thing
Bear with me here, because this bit is genuinely fascinating, and it's the part that most weight-loss conversations, including the ones involving these medications, completely skip over.
The real therapeutic goal is not simply to lose weight. It is to shrink fat cells. These sound like the same thing, but they really aren’t.
Your fat cells are not going anywhere
Here’s something that might surprise you: the number of fat cells you have as an adult stays pretty much fixed. The only change is how big they get. Think of them like tiny storage bags, they can bloat like a beach ball or sit compact and happy like a pillow. In most people who struggle with weight, the problem is not too many bags. It’s bags that have been overfilled.
This is important because it’s the size of those fat cells that creates metabolic problems. Bloated fat cells become stubborn, pro-inflammatory troublemakers. They resist insulin, they recruit immune cells to come and have a bit of an inflammatory party, and they contribute to the very conditions, type 2 diabetes, heart disease, fatty liver, that these drugs are often prescribed to prevent. The goal, then, is to deflate those fat cells. Not destroy them, not cut them out, not just reduce a number on a scale.
Why liposuction is a great way to look thinner and not fix much else
Liposuction physically removes fat cells from just beneath the skin, the thighs, abdomen, and so on. That fat depot is actually the more metabolically harmless one. The fat that causes real metabolic havoc is visceral fat, the stuff packed around your internal organs, deep in your abdomen. Liposuction simply can’t reach it.
Remove the subcutaneous fat cells but keep eating in a way that drives fat storage in the first place, and your body will obligingly fill whatever’s left, including that visceral depot that’s far harder on your health. You might look different after the procedure, but your internal metabolic picture hasn’t improved. The scale and your cardiometabolic risk can tell very different stories.
The real reason most diets fail
Here’s something I want you to genuinely hear, because it might change how you feel about every diet you’ve ever 'failed' at: Hunger beats willpower. Every time. And it’s not a character flaw, it’s biology.
Fat storage is controlled primarily by insulin. Without insulin signaling, fat cells can’t store energy, full stop. And insulin is driven mainly by dietary carbohydrate, especially the refined, processed kind. This is fundamental biochemistry, not a fringe position.
Harvard researcher Professor David Ludwig has shown that when insulin is elevated, your body effectively locks energy inside fat cells, even when you’re eating less. Your brain detects that not enough energy is circulating and does exactly what it’s designed to do: it makes you ravenously hungry. You cave, eat something, and conclude you’re weak. You’re not. You’re human, and your brain just won an argument with your willpower.
This is the underlying problem with most conventional dietary advice: 'eat less and move more' is not wrong exactly; it just treats the symptom (calories in) without addressing the hormonal driver (insulin) that determines how your body uses those calories.
The science-based, two-step approach that actually works
The sequence that makes genuine, sustainable fat loss possible is this:
Step 1: Lower insulin first! This is paramount. The most effective way to do this is to reduce refined carbohydrates, the ones in packets, boxes, and anything that doesn’t look the way it did when it came out of the ground. When insulin drops, fat cells start releasing stored energy. Your metabolism picks up. Hunger naturally reduces, not because you’re white-knuckling it, but because your brain now has enough circulating fuel to stop sounding the alarm. Studies consistently show that people eating this way spontaneously reduce their calorie intake without being told to.
Step 2: Only once insulin is managed and fat burning is underway, if you want to speed things up, structured intermittent fasting is a powerful tool. But doing this step first, before Step 1, is why most calorie-restricted diets eventually fall apart.
It’s not about eating less. It’s about eating differently, so that your body stops hoarding energy and starts releasing it.
7 things about GLP-1 drugs that deserve more airtime
Right, so the drugs work. But here’s what the shiny magazine spreads tend to gloss over.
1. The mental health data is genuinely alarming
This is the one that stops me in my tracks every time, and it is significantly underreported. A large real-world cohort study comparing patients on GLP-1 receptor agonists to those not taking them found:
A 195% increased risk of major depression
A 108% increased risk of anxiety disorders
A 106% increased risk of suicidal behavior
Those are not minor statistical blips. They represent a real, meaningful pattern.
The likely reason is something called anhedonia, a reduced ability to feel pleasure, that appears to arise from the drugs broadly suppressing the brain’s reward system. The problem is that these drugs don’t just reduce your desire for food. They can flatten your enjoyment of pretty much everything: hobbies, socializing, intimacy, and creative pursuits. Things that used to bring you joy just... don’t, as much. And that has real consequences for mental health.
This risk appears significantly higher in people who already have a history of depression, anxiety, or mood disorders, a population that was largely excluded from the clinical trials that gave these drugs their clean bill of health. Worth knowing before you start.
2. You will probably lose muscle as well as fat
Approximately 40% of the total weight lost with semaglutide is fat-free mass, meaning the body is not just losing fat, but also breaking down muscle and reducing bone density in the process. That figure is similar to what you’d see with severe caloric restriction or bariatric surgery, so it’s not unique to these drugs, but it’s also not trivial.
Muscle matters enormously for long-term health and metabolic function. It is the primary tissue responsible for clearing glucose from your bloodstream. Lose enough of it, and you worsen insulin resistance, lower your resting metabolic rate, and make future weight management harder. And here’s the kicker: when people stop the drug, fat mass tends to return quickly. Muscle, particularly in people over 40, does not necessarily bounce back at the same rate.
The practical takeaway: progressive resistance training is non-negotiable if you are on these medications. Not optional. Non-negotiable.
3. Your body may create new fat cells during treatment
Liraglutide (a GLP-1 family member) has been shown to activate a cellular pathway that stimulates the formation of new fat cells. While you’re on the drug and eating very little, these cells stay small and dormant. But stop the drug, return to old habits, and those brand new empty cells are very ready to be filled. Combined with the lean mass you’ve lost, you could end up with more fat cells, less muscle, and a lower metabolic rate than when you started, even if the scales look better in the short term.
4. The cravings come back
The STEP 5 clinical trial followed patients on semaglutide for two years and found significant reductions in sweet cravings and appetite at weeks 20 and 52. By week 104 (the two-year mark), those effects had largely returned to baseline. Your body is very good at adapting to anything you throw at it. Receptors downregulate, signals attenuate, and the drug that felt miraculous at month three starts to feel like background noise. GLP-1 receptors are no exception to this biological rule.
5. Most people stop taking them within two years
Real-world data from both the US and UK show that around 50% of patients discontinue these medications within 12 months. By 24 months, that figure is approximately 67–70%. The reasons are varied: cost (these drugs are expensive), ongoing gastrointestinal discomfort, and mood-related side effects. Combine a waning drug effect with a high discontinuation rate and an unfavorable shifting body composition, and the long-term picture for most patients is considerably less rosy than the clinical trial headlines suggest.
6. Gallstones are a real risk
The gallbladder needs dietary fat to contract and empty properly. When appetite is profoundly suppressed and fat intake falls sharply, bile can sit stagnant, concentrate, and form stones. This is a risk with any very low-fat or very low-calorie approach, not unique to these drugs, but it underscores the importance of maintaining adequate dietary fat even when on this treatment. Which, as it happens, also aligns perfectly with the low-carbohydrate approach we’ll come to shortly.
7. The conventional approach treats the effect, not the cause
This is perhaps the most important point, and I want to make it respectfully, because the doctors and specialists prescribing these medications are genuinely trying to help their patients. The issue is not the prescription. The issue is what typically accompanies it, which is often: take this drug, eat less, and we’ll monitor your weight.
That approach does not address why the fat was being stored in the first place. It does not address insulin. It does not address the dietary patterns that drive insulin. And so when the drug stops working, or the patient stops taking it, the same hormonal environment that created the problem is still there, and as we have seen, potentially worse due to a decreased metabolism.
So what actually works? The case for a smarter approach
Here’s where things get genuinely interesting, because there is a compelling, evidence-based case for these drugs playing a useful role. Just not in the way they’re typically prescribed.
Why some people find carbohydrates impossible to resist
A landmark 1996 study by Ranganath and colleagues, published in the journal Gut, found something fascinating: lean individuals produced a robust GLP-1 response after a carbohydrate-rich meal, which triggered satiety and switched off appetite. People with obesity showed a blunted or absent GLP-1 response, the satiety signal simply didn’t arrive, appetite persisted, and the cravings continued.
Professor Astrup has framed this beautifully: what if, for many people, the issue isn’t a lack of willpower at all, but a broken GLP-1 signaling system? What if the reason some people can’t stop reaching for the biscuit tin isn’t weakness, but a genuine biochemical deficiency in their body’s ‘I’m full’ signal?
That reframe is significant. Because if the real problem is a blunted satiety response to carbohydrates, then these drugs, used smartly, might actually be able to help fix it.
The 90-day micro-dosing protocol: A tool, not a lifestyle
The emerging approach I find genuinely compelling works like this: instead of prescribing full therapeutic doses indefinitely, with all the side effects, costs, and diminishing returns we’ve discussed, you use low doses of a GLP-1 receptor agonist for a defined, short period (around 90 days) as a bridge to help break carbohydrate dependence and establish a lower-carbohydrate dietary pattern.
At lower doses, the drug is sufficient to attenuate carbohydrate cravings without producing the full blast of gastric paralysis, nausea, mood suppression, and lean mass loss that comes with standard therapeutic doses. It’s using a scalpel, whereas the current practice uses a sledgehammer.
Ninety days is enough time to:
Break the neurological habit loop around refined and starchy carbohydrate consumption
Allow insulin levels to begin normalizing in response to dietary change
Establish new food preferences that no longer feel like deprivation
Provide an exit strategy, the drug is a tool with a clear endpoint, not a lifelong commitment
Early clinical data comparing low-dose semaglutide combined with a structured low-carbohydrate program against standard-dose semaglutide alone show outcomes that outperform the standard protocol, better patient experience, fewer side effects, and substantially greater long-term dietary adherence. The drug does the heavy lifting on cravings; the dietary change addresses the underlying hormonal driver. Together, they tackle the problem from both ends.
Why low-carbohydrate eating is the dietary partner this approach needs
Pairing micro-dose GLP-1 support with a low-carbohydrate dietary approach is not arbitrary, it's mechanistically logical. A well-formulated low-carbohydrate diet lowers insulin directly, which unlocks fat cells, increases metabolic rate, and improves the brain's energy sensing so that hunger decreases naturally. It also triggers the liver to produce compounds called ketone bodies, a cleaner, more efficient fuel source the body makes from fat when carbohydrate intake is low, and these play a surprisingly important role in protecting muscle tissue from breaking down.
Research from Brigham Young University has shown that beta-hydroxybutyrate, the primary ketone body produced during low-carbohydrate eating, directly protects muscle cells from the kind of breakdown that plagues high-dose GLP-1 use. In simple terms, when the body is running on this superior fat-derived fuel rather than carbohydrates, it is far less likely to cannibalize muscle for energy. This is how you address the lean mass loss problem associated with GLP-1 therapies, not with more drugs, but by changing the metabolic environment so the body preferentially burns fat rather than muscle.
The result is not just more weight lost. It’s the right kind of weight lost: shrunken fat cells, preserved/increased muscle, improved insulin sensitivity, and a body composition that is genuinely healthier, not simply lighter.
5 practical takeaways you can use right now
Whether or not you’re considering these drugs, the single most important dietary shift you can make for metabolic health is reducing refined and starchy carbohydrates. This means cutting back on anything processed, packaged, or baked, and prioritizing whole proteins, fats, and vegetables instead.
If you are considering a GLP-1 medication, ask your prescriber: What is the dietary plan that goes alongside this prescription? If the answer is vague or amounts to ‘just eat less, push for more,’ the drug without a metabolic strategy is half a solution.
Consider whether a supervised micro-dosing approach, paired with a structured low-carbohydrate program, might offer you better long-term outcomes with fewer risks and no indefinite drug dependency. This is a conversation worth having with a practitioner who specializes in metabolic health.
If you are currently on a GLP-1 medication, start resistance training now, if you’re not already. This is the most effective tool available for preserving lean mass during treatment. Think weights, not walking.
Monitor your mood honestly. If activities that used to bring you pleasure start to feel flat or uninteresting, that is a known effect of these drugs, and it is worth flagging with your prescribing clinician, not brushing off as ‘just a bit flat.’
The bottom line: A tool, not a transformation
GLP-1 receptor agonists are genuinely powerful medications. I have a lot of respect for what they can do in the right hands. But a drug that makes you eat less, without addressing why your body was storing fat in the first place, is not a metabolic solution.
Used smartly, at appropriate doses, for a defined period, as a bridge to genuine dietary and lifestyle change centered on lowering insulin, these medications could help people break through patterns of carbohydrate dependence that they’ve been battling for years. That is a genuinely exciting possibility.
But the best version of this intervention is not self-discipline in a syringe as a permanent substitute for metabolic health. It is a short-term tool to make real change accessible for people who have been struggling, combined with the dietary, exercise, and lifestyle foundations that no drug can replace, and that no drug should have to.
Because here’s the thing: your body is not broken. It is doing exactly what it is designed to do, in response to the hormonal environment you’ve given it. Change the environment, and the body follows. That’s not just naturopathic philosophy, it’s increasingly what the best metabolic science supports.
Want to explore what a metabolic reset could look like for you?
I work with clients across New Zealand and internationally to build personalized, evidence-based metabolic health programs, integrating low-carbohydrate nutrition, naturopathic support, resistance training, and structured fasting protocols. Whether you’re currently on a GLP-1 medication and want to get more out of it, or you’re wondering if there’s a smarter path forward without one, I’d love to help you find your way.
Visit my website to learn more or to book a consultation.
Read more from Stephen Roigard
Stephen Roigard, Integrative Corporate Wellness Consultant
Stephen Roigard is a seasoned health expert specialising in integrative and functional medicine. With over 25 years' experience as a registered naturopath, clinical nutritionist, medical herbalist, and health coach, he empowers individuals and corporate teams to tackle stress, low energy, chronic illness, and mental wellbeing from the root cause. Stephen also brings expertise as a personal trainer and yoga, dance, and martial arts instructor. His corporate wellness work combines science‑backed strategies and behavioural coaching to transform workplace health culture. Passionate about achieving long‑term results, he helps professionals thrive physically, mentally, and emotionally.
